Literature DB >> 12562057

Novel treatments for attention-deficit/hyperactivity disorder in children.

Thomas J Spencer1, Joseph Biederman, Timothy E Wilens, Stephen V Faraone.   

Abstract

Optimal medications for children with attention-deficit/hyperactivity disorder (ADHD) would be effective, well tolerated, and long acting and not cause mood swings or worsen comorbid conditions. Current medications work on brain dopamine and/or norepinephrine systems, which are thought to be involved in ADHD. The medication class with the most evidence of efficacy in ADHD is stimulants, but they may be abused, are effective for only 4 to 12 hours, and may cause mood swings or increase tic severity. In recent years, alternative treatments have been explored. Tricyclic antidepressants have efficacy comparable to that of stimulants but may cause constipation, dry mouth, tremors, blood pressure changes, and potentially serious side effects including cardiac conduction and repolarization delays. Monoamine oxidase inhibitors may improve ADHD symptoms but are associated with severe dietary restrictions. Serotonin reuptake inhibitors have little or no effect in ADHD but may improve comorbid depression. Bupropion, although less effective than stimulants, may improve both ADHD symptoms and comorbid depression. Antihypertensive agents may improve impulsivity, hyperactivity, and comorbid tics but cause sedation or rebound hypertension. Atomoxetine, which is being developed for ADHD, reduces symptoms of ADHD without exacerbating comorbid conditions and is associated with only minor side effects, including subtle changes in blood pressure and heart rate. Before prescribing a treatment, physicians should consider the appropriateness and effectiveness of any medication for children with ADHD, who may be less tolerant of side effects and less able to monitor and express concerns about their well-being than adults.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12562057

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  18 in total

1.  Evaluation of [(11)C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primates.

Authors:  Jean-Dominique Gallezot; David Weinzimmer; Nabeel Nabulsi; Shu-Fei Lin; Krista Fowles; Christine Sandiego; Timothy J McCarthy; R Paul Maguire; Richard E Carson; Yu-Shin Ding
Journal:  Neuroimage       Date:  2010-09-30       Impact factor: 6.556

2.  Evaluation of [11C]TAZA for amyloid β plaque imaging in postmortem human Alzheimer's disease brain region and whole body distribution in rodent PET/CT.

Authors:  Min-Liang Pan; Meenakshi T Mukherjee; Himika H Patel; Bhavin Patel; Cristian C Constantinescu; M Reza Mirbolooki; Christopher Liang; Jogeshwar Mukherjee
Journal:  Synapse       Date:  2016-02-11       Impact factor: 2.562

Review 3.  Psychosocial treatments for attention-deficit/hyperactivity disorder.

Authors:  Laura A Knight; Mary Rooney; Andrea Chronis-Tuscano
Journal:  Curr Psychiatry Rep       Date:  2008-10       Impact factor: 5.285

Review 4.  Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.

Authors:  Jose Martinez-Raga; Carlos Knecht; Nestor Szerman; María I Martinez
Journal:  CNS Drugs       Date:  2013-01       Impact factor: 5.749

5.  Chronic atomoxetine treatment during adolescence decreases impulsive choice, but not impulsive action, in adult rats and alters markers of synaptic plasticity in the orbitofrontal cortex.

Authors:  Haosheng Sun; Paul J Cocker; Fiona D Zeeb; Catharine A Winstanley
Journal:  Psychopharmacology (Berl)       Date:  2011-08-02       Impact factor: 4.530

Review 6.  The utility of rat models of impulsivity in developing pharmacotherapies for impulse control disorders.

Authors:  Catharine A Winstanley
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 7.  Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system.

Authors:  David J Heal; David M Pierce
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 8.  Attention deficit hyperactivity disorder, tics and Tourette's syndrome: the relationship and treatment implications. A commentary.

Authors:  Mary M Robertson
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-02       Impact factor: 4.785

9.  Dissociations between cognitive and motor effects of psychostimulants and atomoxetine in hyperactive DAT-KO mice.

Authors:  Thomas Del'Guidice; Morgane Lemasson; Adeline Etiévant; Stella Manta; Luiz Alexandre V Magno; Guy Escoffier; François S Roman; Jean-Martin Beaulieu
Journal:  Psychopharmacology (Berl)       Date:  2013-08-03       Impact factor: 4.530

10.  Relation of maternal stress during pregnancy to symptom severity and response to treatment in children with ADHD.

Authors:  Natalie Grizenko; Yasaman Rajabieh Shayan; Anna Polotskaia; Marina Ter-Stepanian; Ridha Joober
Journal:  J Psychiatry Neurosci       Date:  2008-01       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.